April 29, 2021: Researchers across the Big Ten Cancer Research Consortium are shedding light on new discoveries that could improve the health and lives of many in years to come through a host of precision medicine strategies. From boosting mitochondrial function in a subpopulation of T cells to analyzing vast amounts of data in populations, and synthesizing a rare compound found in a Native America shrub to combat a protein found in many cancers, these researchers are covering all the bases to make a difference. Learn about them and other investigators on the move in this issue of Across the Consortium. Read More
April 5, 2021 Investigator Spotlight: Channabasavaiah B. Gurumurthy BVSC (DVM), MVSC, PhD, MBA, University of Nebraska Medical Center Research Interests: I am a professor of Pharmacology and Experimental Neuroscience and director of the Mouse Genome Engineering Core Facility. My research interest is in enhancing technologies for biomedical research. I develop genome-editing technologies and custom mouse models useful to research ranging from cancer to neuroscience to COVID-19 research. I am fortunate to work in the interface of two Nobel awarded technologies:... Read More
March 23, 2021: Analysis from the Big Ten Cancer Research Consortium metastatic urothelial carcinoma (mUC) phase 1b study, BTCRC-GU16-051, shows the combination of eribulin mesylate and avelumab is safe and demonstrates efficacy signals that warrant further evaluation in adults with cisplatin-ineligible mUC. In their report, published in European Urology Focus, researchers also noted that the treatment combination was better tolerated and efficacious at lower doses of eribulin mesylate. Monika Joshi, MD, MRCP (pictured left), of Penn State Cancer Institute, led the study in collaboration with Yousef... Read More
March 23, 2021: Rutgers Cancer Institute of New Jersey is leading a single-arm, phase II study for adults with advanced hepatocellular carcinoma and mild liver impairment. Researchers want to learn whether it is safe to give atezolizumab and bevacizumab to participants with advanced liver cancer and Child-Pugh B7 liver dysfunction. They also plan to estimate the overall response rate, disease control rate, duration of response, progression-free survival, and overall survival in these patients using this combined therapy. The study, BTCRC-GI20-457, “A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial),” is now open to accrual at Read More
March 19, 2021: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium highlights current research, innovations, appointments, publications, and general news across member institutions. Read More
Sept. 1, 2021: The Big Ten Cancer Research Consortium Foundation, Inc. (the “Foundation”) requests proposals for the creation and implementation of a development/fundraising program. The Foundation is a philanthropic organization created to raise funds to support collaborative oncology research activities of the Big Ten Cancer Research Consortium (the “Consortium”). The Consortium includes 15 academic cancer centers united to conduct highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities (see https://bigtencrc.org/). The Foundation anticipates a two-year contractual commitment during which the vendor will create and implement a program to raise funds to support the Consortium’s research. The vendor will contract... Read More
March 18, 2021: Big Ten basketball fans have good reason to celebrate this month: The conference is bringing nine teams to the NCAA Men’s Basketball Tournament – leading all other conferences! We’re excited for tip-off, and so are the Big Ten CRC cancer center directors! While basketball teams battle it out on the court, our directors are lacing up their shoes every day to take on cancer. We could not wish for a better team!
Get to know our team:
HOWARD H. BAILEY, MD Director, University of Wisconsin Carbone Cancer Center Key Stats for UW Carbone Cancer Center: One of the original 6 NCI-designated Comprehensive Cancer Centers in 1973. Dr. Charles Heidelberger invented and developed 5-FU here. NCI...
Read More
March 9, 2021: Big Ten Cancer Research Consortium investigators highlighted two ongoing studies during the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, held virtually January 28-31. Melissa Yan, MD (pictured left), a hematology-oncology fellow at the Indiana University School of Medicine, presented a featured poster (FP01.04) on BTCRC-LUN19-396, a phase II study of adjuvant chemotherapy plus atezolizumab in stage IB-IIIA resected non-small cell lung cancer (NSCLC) and clearance of circulating tumor DNA (ctDNA). Emily Sisel (pictured right), an MD candidate at the University of Illinois College of Medicine, presented Read More
March 8, 2021: Big Ten Cancer Research Consortium investigators presented a virtual poster highlighting BTCRC-GU16-043, a Big Ten CRC phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer, during the 2021 Genitourinary Cancers Symposium. The study, led by the University of Michigan Rogel Cancer Center, investigates whether adding guadecitabine, a drug that targets DNA methylation, might increase the proportion of patients with advanced clear cell renal carcinoma (ccRCC) who respond to treatment with durvalumab, a checkpoint inhibitor that... Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube